GERN
Geron Corporation
$1.12
-0.01
(-0.88%)
Mkt Cap
719.57M
Volume
11,232,178
52W Range
1.04-2.01
Sector
Healthcare
Beta
0.61
EPS (TTM)
-0.10 USD
P/E Ratio
-10.15
Revenue (TTM)
204.56M USD
Rev Growth (5Y)
+273.6%
EPS Growth (5Y)
N/A
Company Description
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 183.88M | 76.99M | 237,000 | 596,000 | 1.39M | 253,000 | 460,000 | 1.07M | 1.06M | 6.16M | 36.37M | 1.15M |
| Net Income | (85.78M) | (174.57M) | (184.13M) | (141.90M) | (116.11M) | (75.62M) | (68.55M) | (27.02M) | (27.92M) | (29.54M) | 46,000 | (35.67M) |
| EPS | -0.13 | -0.27 | -0.32 | -0.37 | -0.37 | -0.28 | -0.33 | -0.15 | -0.18 | -0.19 | 0.00 | -0.23 |
| Free Cash Flow | (111.09M) | (219.30M) | (168.57M) | (127.81M) | (95.76M) | (67.05M) | (44.24M) | (21.02M) | (20.56M) | (18.43M) | (24.29M) | 9.22M |
| FCF / Share | -0.17 | -0.34 | -0.30 | -0.34 | -0.29 | -0.25 | -0.23 | -0.12 | -0.13 | -0.12 | -0.15 | 0.06 |
| Operating CF | (111.04M) | (218.62M) | (167.74M) | (127.38M) | (95.56M) | (66.65M) | (43.83M) | (21.01M) | (20.56M) | (18.37M) | (24.20M) | 9.35M |
| Total Assets | 570.54M | 593.78M | 394.08M | 190.57M | 226.03M | 270.73M | 165.52M | 185.28M | 110.31M | 130.25M | 148.76M | 172.51M |
| Total Debt | 251.57M | 121.72M | 85.90M | 55.75M | 55.00M | 29.72M | 2.55M | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 79.44M | 79.02M | 70.02M | 56.84M | 34.87M | 9.93M | 13.64M | 10.84M | 16.60M | 13.08M | 21.52M | 43.06M |
| Book Value | 225.87M | 280.32M | 247.95M | 80.00M | 126.42M | 210.95M | 135.16M | 177.73M | 103.80M | 122.38M | 142.13M | 130.71M |
| Return on Equity | -0.38 | -0.62 | -0.74 | -1.77 | -0.92 | -0.36 | -0.51 | -0.15 | -0.27 | -0.24 | 0.00 | -0.27 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 57.48M | 51.84M | 48.02M | 47.23M | 49.04M | 39.60M | 47.54M | 28.27M | 882,000 | 304,000 | 23,000 | 164,000 |
| Net Income | (16.68M) | (3.64M) | (31.14M) | (18.43M) | (16.38M) | (19.84M) | (25.35M) | (26.45M) | (67.38M) | (55.39M) | (51.97M) | (44.80M) |
| EPS | -0.02 | -0.01 | -0.05 | -0.03 | -0.02 | -0.03 | -0.04 | -0.04 | -0.10 | -0.09 | -0.09 | -0.08 |
| Free Cash Flow | (16.05M) | (63.16M) | (22.10M) | (13.49M) | (27.55M) | (47.98M) | (43.80M) | (58.94M) | (53.68M) | (62.87M) | (41.00M) | (51.03M) |
| FCF / Share | -0.02 | -0.09 | -0.03 | -0.02 | -0.04 | -0.07 | -0.07 | -0.09 | -0.08 | -0.10 | -0.07 | -0.09 |
| Operating CF | (15.83M) | (62.91M) | (22.07M) | (13.58M) | (27.41M) | (47.98M) | (43.95M) | (58.94M) | (53.48M) | (62.25M) | (40.94M) | (50.84M) |
| Total Assets | 519.01M | 534.12M | 570.54M | 567.38M | 555.20M | 562.45M | 593.78M | 444.95M | 449.40M | 482.07M | 394.08M | 413.02M |
| Total Debt | 122.14M | 251.84M | 251.57M | 121.92M | 121.84M | 121.78M | 121.72M | 87.26M | 87.04M | 86.53M | 85.90M | 56.02M |
| Cash & Equiv | 62.64M | 70.78M | 79.44M | 78.12M | 77.73M | 83.75M | 79.02M | 60.34M | 116.94M | 189.76M | 71.14M | 30.71M |
| Book Value | 218.61M | 229.11M | 225.87M | 248.71M | 259.53M | 268.24M | 280.32M | 292.28M | 306.69M | 344.87M | 247.95M | 290.61M |
| Return on Equity | -0.08 | -0.02 | -0.14 | -0.07 | -0.06 | -0.07 | -0.09 | -0.09 | -0.22 | -0.16 | -0.21 | -0.15 |
GERN News
Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)